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Abstract Pathogenic mutations in the phospholam-
ban (PLN) gene may give rise to inherited cardiomy-
opathies due to its role in calcium homeostasis. Sev-
eral PLN mutations have been identified, with the
R14del mutation being the most prevalent cardiomy-
opathy-related mutation in the Netherlands. It is
present in patients diagnosed with arrhythmogenic
cardiomyopathy as well as dilated cardiomyopathy.
Awareness of the phenotype of this PLN mutation is
of great importance, since many carriers remain to
be identified. Patients with the R14del mutation are
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characterised by older age at onset, low-voltage elec-
trocardiograms and a high frequency of ventricular
arrhythmias. Additionally, these patients have a poor
prognosis often with left ventricular dysfunction and
early-onset heart failure. Therefore, when there is
a suspicion of a PLN mutation, cardiac and genetic
screening is strongly recommended.
Keywords Phospholamban · Arrhythmogenic car-
diomyopathy · Dilated cardiomyopathy · Phenotype
Phospholamban
Pathogenic mutations in the phospholamban (PLN)
gene may cause inherited cardiomyopathies due to
the role of PLN in calcium homeostasis [1, 2]. PLN has
a key role in the function of the sarcoplasmic reticu-
lum (SR) which, in turn, is responsible for the distribu-
tion and storage of calcium. During systole, calcium
is released from the SR into the cytosol, facilitating
contraction of the myocyte. During diastole, calcium
must be transported from the cytosol back into the SR
as an essential step for cardiac relaxation. This trans-
port is enabled by the sarcoplasmic reticulum Ca2+-
ATPase pump (SERCA2a), which is regulated by PLN
[1, 3]. In its dephosphorylated form, PLN interacts
with SERCA2a inhibiting calcium transport. Upon
phosphorylation of PLN, its inhibitory effect on
SERCA2a is relieved and calcium storage in the SR
is increased [4, 5]. The activity of SERCA2a and its
interaction with PLN determines the rate of relaxation
and contraction of the cardiac myocyte [1].
Phospholamban mutations
Several mutations have been identified in the PLN
gene in heart failure patients. The first mutation de-
scribed in the PLN gene was an arginine to cysteine
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Fig. 1 Postal code map showing the distribution of PLN
p.Arg14del mutation carriers in the Netherlands. The number
of PLN R14del mutation carriers per region is shown (in paren-
theses: the number of postal code regions, 90 in total)
missense mutation at residue 9 and was associated
with decreased PLN phosphorylation, leading to di-
lated cardiomyopathy (DCM) in a large American fam-
ily [6]. Another mutation involved the conversion of
leucine at position 39 to a premature stop codon,
which was responsible for the development of heart
failure in two large Greek families [7]. A third reported
mutation was a deletion of amino acid 14 (R14del)
and was first described in a large Greek family [8].
Shortly thereafter, this mutation was also identified in
an American and a German family [9, 10].
Interestingly, the R14del mutation appeared to
be the most prevalent cardiomyopathy-related mu-
tation in the Netherlands, being present in 12% of
patients diagnosed with arrhythmogenic cardiomy-
opathy (ACM) and 15% of patients with DCM [2].
All Dutch patients carried the same haplotype, sug-
gesting a founder effect, which was estimated to be
between 575 and 825 years old [11]. The geograph-
ical origin of this haplotype was found to be in the
eastern part of the province of Friesland. Today, over
1000 R14del mutation carriers have been identified
and most mutation carriers live in the northern part
of the Netherlands, with a gradual decline towards
the southern parts (Fig. 1; [11]). Interestingly, a large
Spanish family is also known to carry this mutation
with the identical haplotype [12].
Examination of a large population-based cohort
in the city of Groningen identified 0.07% of those
persons (6/8267) to be R14del mutation carriers [13].
Extrapolating this to the whole of the Netherlands,
including lower prevalences for the more southern
provinces, the total number of R14del mutation car-
riers may be more than 2000 [11]. In order to identify
these unknown mutation carriers, it is crucial to cul-
tivate an awareness of the phenotype of the PLN
mutation.
Phenotype
The R14del mutation results in super-inhibition of
SERCA2a, which is irreversible. Inhibition of calcium
transport and, consequently, cardiac function over
years may lead to ventricular remodelling and fail-
ure [8]. Additionally, myocardial scarring as well as
SR calcium leak may lead to arrhythmias [14]. Con-
sequently, PLN mutation may give rise to clinical
features of DCM as well as ACM. However, the muta-
tion has also been found in asymptomatic individu-
als. This may render their identification challenging.
Several studies have examined patients with PLN mu-
tations and their family members in order to identify
specific phenotypic characteristics that distinguish
them from other patients with DCM or ACM. Their
findings are summarised below.
In patients with the PLN R14del mutation, the on-
set of the disease appears to be age-dependent with
a slightly higher frequency in males [15]. Symptoms
develop most often in the fifth decade with a mean
age at presentation ranging from 40 to 48 years [2, 15,
16]. However, sudden cardiac death may occur earlier
in life and has been reported in patients younger than
30 years old [2].
A striking discovery is that many patients with
a PLN mutation exhibit similar abnormal electro-
cardiographic characteristics. Most members of the
Greek family in which the PLN R14del mutation was
first described had low QRS complex potentials and
decreased R-wave amplitude [8]. This finding was re-
produced in a German family where low R-wave am-
plitudes were found in all adult PLN R14del mutation
carriers regardless of echocardiographic abnormali-
ties [10]. Similarly, within our Dutch population, PLN
mutation carriers frequently show low-voltage elec-
trocardiograms (ECGs) and, additionally, negative T
waves in left precordial leads ([2, 17]; Fig. 2). These
features were not observed in non-mutation carriers,
which indicates a mutation-associated phenotype
[10]. This may be the most striking characteristic and
should raise suspicion of a PLN mutation, includ-
ing taking a family history and considering genetic
counselling. The substrate for these low-voltage ECGs
may be the presence of cardiac fibrosis, which was
a frequent finding at histological examination [8, 18].
Patients with a PLN mutation demonstrate an ar-
rhythmogenic phenotype. This is reflected by a high
rate of positive family history for sudden cardiac death
below the age of 50 years and frequent ventricular
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Fig. 2 Electrocardiogram of a patient with the PLN R14del mutation, with low voltages in the standard leads and negative T
waves in left precordial leads V4 to V6
extrasystoles during Holter monitoring [2, 16, 17]. Ad-
ditionally, DCM patients with a PLN mutation present
with ventricular arrhythmias and experience appro-
priate implantable cardioverter defibrillator (ICD)
therapy more often than DCM patients without a PLN
mutation [2]. In one study, the authors evaluated
possible risk factors for malignant ventricular ar-
rhythmias in a large cohort of individuals carrying the
PLN R14del mutation. They found left ventricular (LV)
ejection fraction <45% and (non-)sustained ventricu-
lar tachycardia (VT) to be independent predictors for
malignant ventricular arrhythmias [15]. These events
may precede end-stage heart failure.
Within the subgroup of patients fulfilling the cri-
teria for ACM, patients with a PLN mutation have
a higher frequency of LV structural and functional
abnormalities [16, 17]. Compared to other mutation
carriers, they show the most pronounced diminished
LV function as determined by echocardiography and
cardiac magnetic resonance imaging (MRI) [16, 19].
Furthermore, cardiac MRI scanning exhibits a typical
pattern of scarring in the inferolateral LV wall, which
is likely reflected by the negative T waves in the infero-
lateral ECG leads. Autopsy findings have corroborated
the presence of extensive fibrosis, which may repre-
sent re-entry circuits that likely contribute to malig-
nant arrhythmias.
Finally, the PLN R14del mutationmay be associated
with a poor prognosis. In the Greek family, the mu-
tation was associated with DCM and death by middle
age [8]. In the German family none of the mutation
carriers survived beyond 50 years of age [10]. Similar
findings were found in a large Dutch population where
mortality rates were increased compared to those in
patients without the PLN mutation, mainly between
the ages of 25 and 74 years [15].
Treatment
Currently, there are no clinical studies regarding the
treatment of patients with a PLN mutation. It is there-
fore recommended that the current guidelines on
heart failure and prevention of sudden cardiac death
(sections on DCM and ACM) be applied to determine
the optimal medical treatment, exercise restriction,
and whether VT ablation or ICD implantation is indi-
cated [20, 21]. In addition, referral to a centre offering
clinical genetics services is recommended.
At present, a Dutch study is randomising asymp-
tomatic PLN mutation carriers to treatment with
eplerenone versus placebo to determine if eplerenone
will slow down progression of the disease (iPhorecast
study). We are awaiting the results.
For patients as well as their doctors a PLN founda-
tion has been established that provides information
on new developments (https://hartspierziektepln.nl).
Conclusion
In the Netherlands the PLN R14del mutation is one
of the most prevalent cardiomyopathy-related muta-
tions. As a founder mutation its origin has been traced
to the northern parts of the Netherlands. PLN muta-
tion carriers have a highly variable phenotype, which
ranges from asymptomatic to cardiomyopathic, in-
cluding clinical features of ACM as well as DCM. The
most striking characteristic is the low-voltage ECGs.
In addition, patients with a PLN mutation are char-






acterised by a late onset of symptoms, an arrhythmo-
genic phenotype, a higher frequency of LV dysfunc-
tion and a poor prognosis. Therefore, upon suspicion
of a PLN mutation, referral to a centre offering clinical
genetics services and cardiac and genetic screening is
strongly recommended.
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